Literature DB >> 24990547

Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study.

Valeria Raparelli1, Marco Proietti, Carmelo Buttà, Paolo Di Giosia, Domenico Sirico, Paolo Gobbi, Salvatore Corrao, Giovanni Davì, Anna Rita Vestri, Francesco Perticone, Gino Roberto Corazza, Francesco Violi, Stefania Basili.   

Abstract

Non-valvular atrial fibrillation (NVAF) represents a major health-care problem, needing an extensive and strict thrombosis prevention for stroke and cardiovascular (CV) disease risks. NVAF management guidelines recommend adequate antithrombotic and anti-atherosclerotic therapies. Medication adherence has been recognized as a pivotal element in health quality promotion and in the achievement of better clinical outcomes. We conducted a post-hoc analysis of the "Atrial fibrillation Registry for Ankle-brachial index Prevalence Assessment-Collaborative Italian Study (ARAPACIS)" with the aim of discerning differences in pharmacological management and medication adherence among NVAF Italian patients. Furthermore, data were analysed according to Italian geographical macro-regions (North, Center, South) to evaluate whether socioeconomic conditions might also influence medication adherence. Thus, we selected 1,366 NVAF patients that fulfilled the Morisky Medication Adherence Scale-4 items. Regional disparities in drug prescriptions were observed. In particular, in high-risk patients (CHA2DS2-VASc ≥2) oral anticoagulants were more prescribed in Northern and Center patients (61 and 60 %, respectively) compared to 53 % of high-risk Southern patients. Also, medication adherence showed a progressive decrease from North to South (78 vs. 60 %, p < 0.001). This disparity was independent of the number of drugs consumed for any reason, since prevalence of poly-therapy among the three macro-regions was similar. Our results show regional differences in NVAF patients' antithrombotic management and medication adherence, potentially reflecting well-known disparities in socioeconomic status among Italian regions. Future interventions promoting campaigns to global health-care education may be desirable to improve clinical outcomes in NVAF patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24990547     DOI: 10.1007/s11739-014-1096-1

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  49 in total

1.  Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study.

Authors:  Alessandro Nobili; Alessandra Marengoni; Mauro Tettamanti; Francesco Salerno; Luca Pasina; Carlotta Franchi; Alfonso Iorio; Maura Marcucci; Salvatore Corrao; Giuseppe Licata; Pier Mannuccio Mannucci
Journal:  Eur J Intern Med       Date:  2011-09-29       Impact factor: 4.487

2.  Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy.

Authors:  Francesco Violi; Giovanni Daví; William Hiatt; Gregory Y H Lip; Gino R Corazza; Francesco Perticone; Marco Proietti; Pasquale Pignatelli; Anna R Vestri; Stefania Basili
Journal:  J Am Coll Cardiol       Date:  2013-08-14       Impact factor: 24.094

3.  Video in clinical medicine. Ankle-brachial index for assessment of peripheral arterial disease.

Authors:  S Marlene Grenon; Joel Gagnon; York Hsiang
Journal:  N Engl J Med       Date:  2009-11-05       Impact factor: 91.245

4.  Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study.

Authors:  Alessandro Nobili; Giuseppe Licata; Francesco Salerno; Luca Pasina; Mauro Tettamanti; Carlotta Franchi; Luigi De Vittorio; Alessandra Marengoni; Salvatore Corrao; Alfonso Iorio; Maura Marcucci; Pier Mannuccio Mannucci
Journal:  Eur J Clin Pharmacol       Date:  2011-01-11       Impact factor: 2.953

Review 5.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

6.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 7.  Medication adherence: its importance in cardiovascular outcomes.

Authors:  P Michael Ho; Chris L Bryson; John S Rumsfeld
Journal:  Circulation       Date:  2009-06-16       Impact factor: 29.690

8.  Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy.

Authors:  D Ferro; L Loffredo; L Polimeni; F Violi
Journal:  Intern Emerg Med       Date:  2007-03-31       Impact factor: 3.397

Review 9.  Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review.

Authors:  Dedan Opondo; Saied Eslami; Stefan Visscher; Sophia E de Rooij; Robert Verheij; Joke C Korevaar; Ameen Abu-Hanna
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

10.  Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF).

Authors:  Paulus Kirchhof; Bettina Ammentorp; Harald Darius; Raffaele De Caterina; Jean-Yves Le Heuzey; Richard John Schilling; Josef Schmitt; Jose Luis Zamorano
Journal:  Europace       Date:  2013-10-01       Impact factor: 5.214

View more
  6 in total

1.  Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study.

Authors:  Marco Proietti; Alessandro Nobili; Valeria Raparelli; Laura Napoleone; Pier Mannuccio Mannucci; Gregory Y H Lip
Journal:  Clin Res Cardiol       Date:  2016-05-31       Impact factor: 5.460

2.  Neighbourhood socio-economic status and all-cause mortality in adults with atrial fibrillation: A cohort study of patients treated in primary care in Sweden.

Authors:  Per Wändell; Axel C Carlsson; Danijela Gasevic; Jan Sundquist; Kristina Sundquist
Journal:  Int J Cardiol       Date:  2015-09-21       Impact factor: 4.164

3.  Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.

Authors:  Valeria Raparelli; Daniele Pastori; Serena Francesca Pignataro; Anna Rita Vestri; Pasquale Pignatelli; Roberto Cangemi; Marco Proietti; Giovanni Davì; William Robert Hiatt; Gregory Yoke Hong Lip; Gino Roberto Corazza; Francesco Perticone; Francesco Violi; Stefania Basili
Journal:  Intern Emerg Med       Date:  2018-03-26       Impact factor: 3.397

4.  Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial.

Authors:  Marco Proietti; Valeria Raparelli; Brian Olshansky; Gregory Y H Lip
Journal:  Clin Res Cardiol       Date:  2015-11-02       Impact factor: 5.460

Review 5.  The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations.

Authors:  Anna Plitt; Sameer Bansilal
Journal:  J Atr Fibrillation       Date:  2017-02-28

6.  Antithrombotic Preventive Medication Prescription Redemption and Socioeconomic Status in Hungary in 2016: A Cross-Sectional Study.

Authors:  Attila Juhász; Csilla Nagy; Orsolya Varga; Klára Boruzs; Mária Csernoch; Zoltán Szabó; Róza Ádány
Journal:  Int J Environ Res Public Health       Date:  2020-09-19       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.